LifeVantage (LFVN) investor relations material

Executive summary

• Q4 FY2026 revenue was $42.4M, down 23.1% year-over-year; full year revenue was $182.6M, down 20.1% year-over-year.

• New CEO emphasizes differentiated science, strong margins, and untapped potential as growth drivers.

• Leadership transition acknowledged, with optimism about long-term value creation and disciplined capital allocation.

• Strategic priorities include strengthening the brand, enhancing consumer relevance, and improving operational excellence and profitability.

• Declines attributed to lower order volume, smaller average order size, and cycling of strong prior-year product sales, partially offset by new product acquisition.

Financial highlights

• Q4 net revenue was $42.4M, down 23.1% year-over-year, and down 3.1% sequentially from Q3.

• Gross profit margin for Q4 was 78% (vs. 79.9% prior year); full year margin was 77.6% (vs. 80.4%).

• GAAP net income for Q4 was $1.3M ($0.10 per diluted share), down from $2M ($0.15 per share) year-over-year; full year was $0.40 (vs. $0.75 prior year).

• Adjusted EBITDA for Q4 was $2.7M (6.5% of revenue), compared to $4.8M (8.7% of revenue) a year ago; full year was $13.7M (vs. $22.1M prior year).

• Cash position at year-end was $14.9M with no debt.

Segment performance

• Americas revenue for Q4 fell 24.8% year-over-year to $32.7M; Asia-Pacific and Europe fell 16.9% to $9.7M.

• Full year Americas revenue declined 23.2%; Asia-Pacific & Europe declined 6.9%.

• Subscription-based revenue represented over 75% of total revenue, with improved customer retention metrics year-over-year.

• Active accounts dropped 21.2% year-over-year to 104,000, with both consultant and customer counts down double digits.

• Lower sales of MindBody GLP-1 System and overall order declines impacted results, partially offset by LoveBiome acquisition.